ANIP
ANALYST COVERAGE10 analysts
BUY
+59.0%upside to target
Buy
770%
Hold
330%
7 Buy (70%)3 Hold (30%)0 Sell (0%)
Full report →
PRICE
Prev Close
79.58
Open
79.48
Day Range76.67 – 79.48
76.67
79.48
52W Range56.71 – 99.50
56.71
99.50
50% of range
VOLUME & SIZE
Avg Volume
372.9K
FUNDAMENTALS
P/E Ratio
19.9x
EPS (TTM)
Div Yield
No dividend
Beta
0.81
Market-like
TECHNICAL
RSI (14)
53
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 102 days
Aug 28
Key MetricsTTM
Market Cap$1.77B
Revenue TTM$923.71M
Net Income TTM$89.67M
Free Cash Flow$165.60M
Gross Margin65.9%
Operating Margin13.4%
Net Margin9.7%
Return on Equity17.3%
Return on Assets6.3%
Debt / Equity0.58
Current Ratio3.12
EPS TTM$4.29

ANIP News

About

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Patrick Walsh
Muthusamy ShanmugamHead of R&D, Chief Operating Officer of New Jersey Operations & Director
Thomas Andrew RowlandSenior Vice President & Head of Established Brands
Elizabeth PowellChief Compliance Officer & Head of Legal of Rare Disease
Krista L. DavisSenior Vice President & Chief Human Resources Officer
Meredith W. CookSenior Vice President, General Counsel & Corporate Secretary
Mary PaoChief Medical Officer
Christopher K. MutzSenior Vice President & Head of Rare Disease
Chad GassertSenior Vice President of Corporate Development & Strategy
Nikhil LalwaniPresident, Chief Executive Officer & Director
Ori GutwergSenior Vice President of Generics
Stephen CareySenior Vice President of Finance & Chief Financial Officer